You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):1類創新藥富馬酸安奈克替尼膠囊“UNECRITINIB (TQ-B3101)”獲批上市
格隆匯 04-30 16:37

格隆匯4月30日丨中國生物製藥(01177.HK)宣佈,集團自主研發的1類創新藥富馬酸安奈克替尼膠囊"Unecritinib (TQ-B3101)"(商品名:安柏尼)已獲得中國國家藥品監督管理局的上市批准,用於ROS1陽性的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者的治療。這是首個獲批用於治療ROS1陽性的局部晚期或轉移性非小細胞肺癌成人患者的國產靶向藥。

安奈克替尼是集團自主研發的一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制劑。其研究結果先後發佈在美國臨牀腫瘤學會(ASCO)年會、美國血液學會(ASH)年會、歐洲肺癌大會(ELCC)、Frontiers inPharmacology和Signal Transduction and Targeted Therapy等國際知名學術會議或期刊。2022年6月,基於一項《評價TQ-B3101膠囊單藥治療ROS1陽性NSCLC受試者療效和安全性的II期單臂、多中心臨牀研究》(TQ-B3101-II-01),安奈克替尼在中國遞交新藥上市申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account